NCT02878681View on ClinicalTrials.gov

24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Visual Impairment Due to Diabetic Macular Edema
Interventions
DRUG

Ranibizumab

0.5 mg intravitreal injections

DRUG

Aflibercept

2 mg intravitreal injections

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY